<table id="id_6641e258-1d9d-4516-876b-787d8083d43c" width="430.000" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption id="id_b3c765e1-5d4a-4777-9be9-5a05972bfc1b">Table 3 TOTAL SYMPTOM SCORE (TSS) Changes in a 4-Week Clinical Trial in Patients with Perennial Allergic Rhinitis</caption>
<col align="center" width="30.0%"></col>
<col align="center" width="20.0%"></col>
<col align="center" width="20.0%"></col>
<col align="center" width="30.0%"></col>
<thead>
<tr id="id_85536b56-2001-4c73-9ddf-cec9a34ba6aa" stylecode="Botrule">
<td align="left" stylecode="Rrule" valign="top">Treatment Group<br/>(n)</td>
<td align="left" stylecode="Rrule" valign="top">Mean Baseline<footnote id="id-253cfccf-9bd2-4466-81b3-7f127e8ec1ff">At baseline, average of total symptom score (sum of 5 individual nasal symptoms and 3 non-nasal symptoms, each symptom scored 0 to 3 where 0=no symptom and 3=severe symptoms) of at least 10 was required for trial eligibility. TSS ranges from 0=no symptoms to 24=maximal symptoms.</footnote>
<br/>(sem)</td>
<td align="left" stylecode="Rrule" valign="top">Change from Baseline<footnote id="id-dc66c6ad-79fe-4eb3-bd9b-7fb11485bffc">Mean reduction in TSS averaged over the 4-week treatment period.</footnote>
<br/>(sem)</td>
<td align="left" valign="top">Placebo Comparison<br/>(<content stylecode="italics">P</content>-value)</td>
</tr>
</thead>
<tbody>
<tr id="id_7b9d108d-5e2b-4207-b48e-a2b96eb064e6" stylecode="Toprule">
<td align="left" valign="top">CLARINEX 5.0 mg (337)</td>
<td align="left" stylecode="Toprule" valign="top">12.37 (0.18)</td>
<td align="left" stylecode="Toprule" valign="top">-4.06 (0.21)</td>
<td align="left" valign="top">
<content stylecode="italics">P</content>=0.01</td>
</tr>
<tr id="id_d38ad1a5-b007-4bc0-a8bc-43b2ac83f1b1" stylecode="Botrule">
<td align="left" valign="top">Placebo (337)</td>
<td align="left" valign="top">12.30 (0.18)</td>
<td align="left" valign="top">-3.27 (0.21)</td>
<td align="left" valign="top"></td>
</tr>
</tbody>
</table>